← boardnext 2027-04
LONA
LeonaBiodistress 6/10 · elevated risk$7.60+1%today-35% from 52w high
Lead: HER2-
Revenue
pre-revenue
Liquidity
$78M
Runway
1.5 yrs
Shares 1y
-76%
Price & events
+23.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.5%
1D
-2.7%
1W
-9.0%
1M
-11.8%
3M
+30.8%
6M
+54.5%
1Y
-77.4%
2Y
-92.5%
5Y
-97.4%
All
Overview
- Market Cap
- $71.39M
- Volume
- 721
- 52 Week Range
- $3.57 – $11.68
- Total Shares
- 9.39M
- Float Shares
- 5.62M
- Short %
- 0.76%
- % Held by Insiders
- 4.51%
- % Held by Institutions
- 70.41%
- RVOL
- 0.02x
- Beta
- 2.02
Pipeline stages · 1 programs
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-04 Estimated 50% readout ~2027-06-15 | Phase 3 | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Metastatic Breast Cancer | — | recruiting |
Catalyst news & presentations · 9
- second half of 2027Guided 55%readoutPhase 3Lasofoxifene · Topline data for Phase 3 ELAINE-3 trialSEC 8-K
- fourth quarter of 2026Guided 70%enrollment completesecondaryPhase 3Lasofoxifene · Complete enrollment of Phase 3 ELAINE-3 trialSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 2ATH-1105 · Initiate Phase 2 proof-of-concept study in ALS patientsSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2025readoutPhase 1ATH-1105 · Full healthy volunteer data from Phase 1 trial.SEC 8-K
- 2025trial initiationsecondaryATH-1105 · On track to enable dosing ALS patients in 2025.SEC 8-K
- May 13, 2025conferencedata presentationsecondaryATH-1105 · Presentation of Phase 1 and nonclinical efficacy data at ALS Drug Development Summit.SEC 8-K
- year-end 2024readoutPhase 1ATH-1105 · Completion of Phase 1 healthy volunteer studySEC 8-K
- 2024-11-07trial discontinuedfosgonimeton · Paused further development of fosgonimeton after LIFT-AD resultsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $18 (+137% upside) · 2 analysts
- 2026-05-27Piper SandlerOverweight
- 2026-02-19MizuhoNeutral → Outperform
Competitors — HER2-
- NVSEFNOVARTIS AG$292.0B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- JAZZJazz Pharmaceuticals plc$15.7B · D0
- RLAYRelay Therapeutics, Inc.$3.6B · D6
- ZYMEZymeworks Inc.$1.7B · D1
- OLMAOlema Pharmaceuticals, Inc.$990M · D4
- ARVNARVINAS, INC.$525M · D1
- PRLDPrelude Therapeutics Inc$307M · D6
- ABPOAbpro Holdings, Inc.$1M · D5
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-17Obituary for Lona Rachel (Jayne) Haynes - Borek Jennings Funeral Homes
- 2026-07-17Lona ‘Ruth’ Wilson - Hampshire Review
- 2026-07-17Mizuho Securities Remains a Buy on LeonaBio (LONA) - The Globe and Mail
- 2026-07-15Lona Lee DYER Obituary (1934 - 2026) - Spokane, WA - Spokesman-Review - Legacy | Obituary Search
- 2026-07-13Obituary for Lona "Lonnie" (Hamilton) VanGilder - Czup Funeral Home
- 2026-07-13LeonaBio Inc. (LONA) Gains 2.24% as Stock Approaches Key Resistance at $10.08 - Stop Loss Guidance - dars.gov.et
- 2026-07-10WIT Studio Unveils ‘LONA,’ Spotlights ‘The One Piece’ and ‘Candy Caries’ at AX - Animation Magazine
- 2026-07-10LeonaBio (LONA) awards 28,000 stock options tied to Perceptive Advisors board role - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.